September 29, 2026

First MCT8 deficiency therapy approved

Clinical studies showed reductions in circulating thyroid hormone levels and changes in heart rate and systolic blood pressure.

MDSpire News

September 28, 2026

FDA approves new treatment for FOP

Total new heterotopic ossification volume decreased with treatment and increased with placebo at week 24.

MDSpire News

September 28, 2026

FDA expands treatment in nephrotic syndrome

The indication marks an additional use for a therapy previously approved for certain cancers and active lupus nephritis.

MDSpire News

September 18, 2026

FDA approves gene therapy for MPS IIIA

The one-time intravenous treatment uses adeno-associated virus serotype 9 to deliver a functional copy of the SGSH gene.

MDSpire News

September 14, 2026

FDA broadens APDS treatment options

An 8-patient study evaluated safety and pharmacokinetics in the younger pediatric population.

MDSpire News

September 14, 2026

FDA approves muscle-targeted SMA therapy

The therapy inhibits myostatin signaling and is used with survival motor neuron 2-targeted treatment.

MDSpire News

September 14, 2026

FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.

MDSpire News

September 04, 2026

FDA approves first therapy for Alexander disease

The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.

MDSpire News

August 31, 2026

Do antihistamines help atopic dermatitis?

First-generation H1 antihistamines likely increase cognitive impairment, with cognitive effects differing among second-generation antihistamines.

MDSpire News

August 28, 2026

FDA approves XFG-adapted COVID-19 vaccine

The 2026 to 2027 formulation aligns with FDA guidance on the preferred composition for COVID-19 vaccines beginning this fall.

MDSpire News